Based on the genetic heterogeneity of the observed mutation spectrum, sequencing of the entire open‐reading frame (ORF) of BRCA1 and BRCA2 using tumor‐derived DNA is required to identify the patients who may benefit from this treatment. Here, BRCA2 is linked to neoplasm.